Anika Therapeutics (ANIK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 41,921 | 40,523 | 42,971 | 41,465 | 44,302 |
| Cost of Goods | 14,556 | 15,895 | 16,642 | 16,521 | 15,330 |
| Gross Profit | 27,365 | 24,628 | 26,329 | 24,944 | 28,972 |
| Operating Expenses | 27,760 | 30,586 | 90,752 | 33,139 | 32,933 |
| Operating Income | 161 | -5,063 | -63,781 | -7,674 | -3,631 |
| Other Income | 595 | 592 | 577 | 635 | 561 |
| Pre-tax Income | 756 | -4,471 | -63,204 | -7,039 | -3,070 |
| Income Tax | 844 | 43 | -204 | -463 | -329 |
| Net Income Continuous | -88 | -4,514 | -63,000 | -6,576 | -2,741 |
| Net Income | $-88 | $-4,514 | $-63,000 | $-6,576 | $-2,741 |
| EPS Basic Total Ops | -0.01 | -0.31 | -4.29 | -0.45 | -0.19 |
| EPS Basic Continuous Ops | -0.01 | -0.31 | -4.30 | -0.45 | -0.19 |
| EPS Diluted Total Ops | -0.01 | -0.31 | -4.29 | -0.45 | -0.19 |
| EPS Diluted Continuous Ops | -0.01 | -0.31 | -4.30 | -0.45 | -0.19 |
| EPS Diluted Before Non-Recurring Items | 0.00 | 0.09 | 0.05 | 0.00 | -0.06 |
| EBITDA(a) | $2,219 | $-3,000 | $1,983 | $-4,132 | $-81 |